217 related articles for article (PubMed ID: 31914840)
1. Checkpoint inhibition therapy as possible frontline therapy for Hodgkin lymphoma.
Khurana A; Armand P; Ansell SM
Leuk Lymphoma; 2020 May; 61(5):1063-1074. PubMed ID: 31914840
[TBL] [Abstract][Full Text] [Related]
2. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab for the treatment of Hodgkin Lymphoma.
Al Hadidi SA; Lee HJ
Expert Opin Biol Ther; 2020 Nov; 20(11):1275-1282. PubMed ID: 33006479
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Significance of Immune-checkpoint Molecule PD-L1 in Classical Hodgkin Lymphoma: A Clinicopathologic Study of 120 Cases.
Kubes V; Kren L; Sokol F; Michalka J; Muzik J; Arpas T; Krenova Z; Kral Z
In Vivo; 2023; 37(4):1735-1742. PubMed ID: 37369476
[TBL] [Abstract][Full Text] [Related]
5. Paradigm Shifts in Hodgkin Lymphoma Treatment: From Frontline Therapies to Relapsed Disease.
Burton C; Allen P; Herrera AF
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e433502. PubMed ID: 38728605
[TBL] [Abstract][Full Text] [Related]
6. Programmed Cell Death-One Inhibition Therapy in Classical Hodgkin Lymphoma.
Al-Hadidi SA; Chuang HH; Miranda RN; Lee HJ
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e105-e111. PubMed ID: 33160934
[TBL] [Abstract][Full Text] [Related]
7. Optimizing checkpoint inhibitors therapy for relapsed or progressive classic Hodgkin lymphoma by multiplex immunohistochemistry of the tumor microenvironment.
Carbone A; Gloghini A; Pruneri G; Dolcetti R
Cancer Med; 2019 Jun; 8(6):3012-3016. PubMed ID: 31070022
[TBL] [Abstract][Full Text] [Related]
8. [Checkpoint inhibitors in Hodgkin lymphoma].
Sasse S; Momotow J; Engert A
Internist (Berl); 2020 Jul; 61(7):660-668. PubMed ID: 32462248
[TBL] [Abstract][Full Text] [Related]
9. Novel agents in the treatment of Hodgkin lymphoma: Biological basis and clinical results.
Younes A; Ansell SM
Semin Hematol; 2016 Jul; 53(3):186-9. PubMed ID: 27496310
[TBL] [Abstract][Full Text] [Related]
10. [Microenvironment in classical Hodgkin lymphoma].
Mottok A
Pathologe; 2020 May; 41(3):254-260. PubMed ID: 32239325
[TBL] [Abstract][Full Text] [Related]
11. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
Roemer MGM; Redd RA; Cader FZ; Pak CJ; Abdelrahman S; Ouyang J; Sasse S; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman J; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Ansell S; Kato K; Farsaci B; Sumbul A; Armand P; Neuberg DS; Pinkus GS; Ligon AH; Rodig SJ; Shipp MA
J Clin Oncol; 2018 Apr; 36(10):942-950. PubMed ID: 29394125
[TBL] [Abstract][Full Text] [Related]
12. Future directions in Hodgkin lymphoma: checkpoint inhibitors and beyond.
Desai S; Ansell SM
Leuk Lymphoma; 2021 Aug; 62(8):1795-1804. PubMed ID: 33602008
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
Roemer MG; Advani RH; Ligon AH; Natkunam Y; Redd RA; Homer H; Connelly CF; Sun HH; Daadi SE; Freeman GJ; Armand P; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Rodig SJ; Shipp MA
J Clin Oncol; 2016 Aug; 34(23):2690-7. PubMed ID: 27069084
[TBL] [Abstract][Full Text] [Related]
14. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
15. Incorporating novel agents into frontline treatment of Hodgkin lymphoma.
Kambhampati S; Herrera AF
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):706-716. PubMed ID: 36485085
[TBL] [Abstract][Full Text] [Related]
16. Anti-PD-1 Antibodies as a Therapeutic Strategy in Classical Hodgkin Lymphoma.
Jain MD; Kuruvilla J
Drugs; 2017 Oct; 77(15):1645-1655. PubMed ID: 28819821
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibition in classical hodgkin lymphoma.
Pezeshki PS; Eskian M; Hamblin MR; Rezaei N
Expert Rev Anticancer Ther; 2021 Sep; 21(9):1003-1016. PubMed ID: 33857395
[No Abstract] [Full Text] [Related]
18. 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial.
Gerhard-Hartmann E; Goergen H; Bröckelmann PJ; Mottok A; Steinmüller T; Grund J; Zamò A; Ben-Neriah S; Sasse S; Borchmann S; Fuchs M; Borchmann P; Reinke S; Engert A; Veldman J; Diepstra A; Klapper W; Rosenwald A
Br J Haematol; 2022 Jan; 196(1):116-126. PubMed ID: 34520052
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of pembrolizumab for classical Hodgkin lymphoma.
Manji F; Laister RC; Kuruvilla J
Expert Rev Hematol; 2022 Apr; 15(4):285-293. PubMed ID: 35389317
[TBL] [Abstract][Full Text] [Related]
20. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
Bair SM; Strelec LE; Feldman TA; Ahmed G; Armand P; Shah NN; Singavi AN; Reddy N; Khan N; Andreadis C; Vu K; Huntington SF; Giri S; Ujjani C; Howlett C; Faheem M; Youngman MR; Nasta SD; Landsburg DJ; Schuster SJ; Svoboda J
Oncologist; 2019 Jul; 24(7):955-962. PubMed ID: 30568021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]